Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
